Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 18 | 2023 | 1059 | 2.820 |
Why?
|
Neoplastic Stem Cells | 10 | 2021 | 142 | 1.530 |
Why?
|
Neoplasms | 12 | 2023 | 2809 | 1.480 |
Why?
|
Carcinoma, Squamous Cell | 8 | 2022 | 1079 | 1.460 |
Why?
|
Medical Oncology | 4 | 2023 | 350 | 1.420 |
Why?
|
Artificial Intelligence | 6 | 2023 | 261 | 1.340 |
Why?
|
Salivary Gland Neoplasms | 6 | 2021 | 65 | 1.320 |
Why?
|
Oropharyngeal Neoplasms | 4 | 2022 | 124 | 1.300 |
Why?
|
Papillomavirus Infections | 4 | 2022 | 242 | 1.180 |
Why?
|
Carcinoma, Adenoid Cystic | 5 | 2018 | 28 | 1.160 |
Why?
|
Hematology | 1 | 2023 | 29 | 0.940 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2022 | 6 | 0.930 |
Why?
|
Biomarkers, Tumor | 6 | 2022 | 1450 | 0.920 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1063 | 0.910 |
Why?
|
Lenses | 1 | 2022 | 4 | 0.890 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2019 | 582 | 0.890 |
Why?
|
Medicine | 1 | 2022 | 87 | 0.850 |
Why?
|
Carcinoma | 2 | 2022 | 431 | 0.840 |
Why?
|
Humans | 77 | 2023 | 84431 | 0.830 |
Why?
|
Lens, Crystalline | 1 | 2022 | 68 | 0.830 |
Why?
|
Diagnostic Tests, Routine | 1 | 2021 | 62 | 0.800 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2020 | 13 | 0.800 |
Why?
|
Specimen Handling | 1 | 2021 | 96 | 0.790 |
Why?
|
Academies and Institutes | 1 | 2020 | 30 | 0.780 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2020 | 35 | 0.780 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 17 | 0.780 |
Why?
|
Microsatellite Instability | 4 | 2021 | 40 | 0.780 |
Why?
|
Ovarian Neoplasms | 3 | 2022 | 723 | 0.760 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2021 | 1196 | 0.750 |
Why?
|
Neurofibromin 1 | 1 | 2019 | 8 | 0.740 |
Why?
|
ras Proteins | 1 | 2020 | 128 | 0.740 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2020 | 136 | 0.730 |
Why?
|
Mouth Neoplasms | 4 | 2023 | 196 | 0.730 |
Why?
|
Cyclin D1 | 1 | 2019 | 83 | 0.720 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2020 | 290 | 0.720 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2022 | 2401 | 0.720 |
Why?
|
Lung Neoplasms | 3 | 2023 | 2235 | 0.710 |
Why?
|
Adenocarcinoma | 3 | 2023 | 1155 | 0.710 |
Why?
|
Leadership | 1 | 2020 | 130 | 0.700 |
Why?
|
Machine Learning | 6 | 2023 | 215 | 0.670 |
Why?
|
Triple Negative Breast Neoplasms | 4 | 2022 | 133 | 0.660 |
Why?
|
Cell Proliferation | 8 | 2021 | 1566 | 0.650 |
Why?
|
Neoplasm Staging | 7 | 2022 | 1929 | 0.640 |
Why?
|
Carcinoma, Mucoepidermoid | 4 | 2019 | 17 | 0.630 |
Why?
|
Transcriptome | 2 | 2021 | 559 | 0.620 |
Why?
|
Precision Medicine | 1 | 2021 | 383 | 0.600 |
Why?
|
Patient Selection | 1 | 2020 | 684 | 0.590 |
Why?
|
Mutation | 6 | 2021 | 3904 | 0.580 |
Why?
|
Papillomaviridae | 3 | 2022 | 156 | 0.580 |
Why?
|
Thyroid Neoplasms | 1 | 2020 | 404 | 0.570 |
Why?
|
Breast Neoplasms | 6 | 2022 | 2845 | 0.570 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2021 | 1195 | 0.570 |
Why?
|
Cell Line, Tumor | 16 | 2021 | 2395 | 0.510 |
Why?
|
Xenograft Model Antitumor Assays | 11 | 2021 | 455 | 0.490 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 3 | 2018 | 29 | 0.460 |
Why?
|
Interleukin-6 | 3 | 2020 | 244 | 0.440 |
Why?
|
Antineoplastic Agents | 8 | 2022 | 2329 | 0.440 |
Why?
|
Tumor Burden | 4 | 2022 | 280 | 0.400 |
Why?
|
Female | 33 | 2022 | 43875 | 0.400 |
Why?
|
Stomach Neoplasms | 3 | 2023 | 261 | 0.400 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2022 | 1262 | 0.390 |
Why?
|
Prognosis | 7 | 2023 | 3626 | 0.380 |
Why?
|
Immunotherapy | 8 | 2023 | 602 | 0.370 |
Why?
|
Mice | 21 | 2021 | 11056 | 0.360 |
Why?
|
Tumor Microenvironment | 6 | 2023 | 386 | 0.350 |
Why?
|
Neoplasm Grading | 2 | 2020 | 346 | 0.340 |
Why?
|
Models, Biological | 3 | 2022 | 1731 | 0.330 |
Why?
|
Estrogen Receptor alpha | 2 | 2019 | 142 | 0.330 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2021 | 288 | 0.320 |
Why?
|
Mice, SCID | 6 | 2018 | 251 | 0.320 |
Why?
|
Cisplatin | 6 | 2022 | 603 | 0.310 |
Why?
|
Middle Aged | 19 | 2022 | 24746 | 0.310 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2017 | 13 | 0.300 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2017 | 28 | 0.300 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2018 | 370 | 0.300 |
Why?
|
B7-H1 Antigen | 4 | 2023 | 243 | 0.300 |
Why?
|
Animals | 25 | 2022 | 26192 | 0.300 |
Why?
|
Algorithms | 4 | 2023 | 1812 | 0.290 |
Why?
|
Receptor, ErbB-2 | 4 | 2022 | 210 | 0.280 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 1362 | 0.270 |
Why?
|
Colorectal Neoplasms | 3 | 2021 | 903 | 0.260 |
Why?
|
Neoplasm Proteins | 2 | 2020 | 532 | 0.260 |
Why?
|
Receptors, Interleukin-6 | 2 | 2021 | 17 | 0.260 |
Why?
|
Paclitaxel | 4 | 2022 | 459 | 0.250 |
Why?
|
Membrane Glycoproteins | 2 | 2016 | 427 | 0.250 |
Why?
|
Proportional Hazards Models | 3 | 2023 | 855 | 0.250 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2020 | 918 | 0.240 |
Why?
|
Male | 20 | 2022 | 40422 | 0.240 |
Why?
|
Xerostomia | 1 | 2023 | 10 | 0.240 |
Why?
|
Mouth Diseases | 1 | 2023 | 15 | 0.230 |
Why?
|
Oral Medicine | 1 | 2023 | 4 | 0.230 |
Why?
|
Cohort Studies | 5 | 2021 | 2717 | 0.230 |
Why?
|
Piperazines | 3 | 2019 | 269 | 0.230 |
Why?
|
Drug Design | 1 | 2023 | 123 | 0.230 |
Why?
|
Re-Irradiation | 1 | 2022 | 16 | 0.220 |
Why?
|
Pyridines | 3 | 2019 | 305 | 0.220 |
Why?
|
Uncertainty | 1 | 2022 | 71 | 0.220 |
Why?
|
Polycomb Repressive Complex 1 | 1 | 2021 | 4 | 0.220 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 123 | 0.210 |
Why?
|
Liquid Biopsy | 1 | 2021 | 31 | 0.210 |
Why?
|
Cloud Computing | 1 | 2021 | 7 | 0.210 |
Why?
|
Precancerous Conditions | 1 | 2023 | 194 | 0.210 |
Why?
|
Data Accuracy | 1 | 2021 | 28 | 0.210 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 69 | 0.210 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 47 | 0.200 |
Why?
|
Neoplasm Metastasis | 3 | 2020 | 1054 | 0.200 |
Why?
|
Drug Monitoring | 1 | 2022 | 118 | 0.200 |
Why?
|
DNA, Viral | 1 | 2022 | 263 | 0.200 |
Why?
|
Cellular Reprogramming | 1 | 2021 | 36 | 0.200 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.200 |
Why?
|
Neck Dissection | 1 | 2021 | 67 | 0.200 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2022 | 62 | 0.200 |
Why?
|
Endogenous Retroviruses | 1 | 2020 | 9 | 0.200 |
Why?
|
Acetophenones | 1 | 2020 | 27 | 0.200 |
Why?
|
Receptors, Progesterone | 2 | 2019 | 165 | 0.200 |
Why?
|
Neoplasms, Experimental | 2 | 2020 | 271 | 0.190 |
Why?
|
Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 21 | 0.190 |
Why?
|
Recombinational DNA Repair | 1 | 2020 | 9 | 0.190 |
Why?
|
4-1BB Ligand | 1 | 2020 | 1 | 0.190 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2020 | 18 | 0.190 |
Why?
|
Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2020 | 15 | 0.190 |
Why?
|
Aged | 11 | 2021 | 18157 | 0.190 |
Why?
|
Wnt Signaling Pathway | 1 | 2021 | 87 | 0.190 |
Why?
|
Protein Kinase Inhibitors | 3 | 2019 | 588 | 0.190 |
Why?
|
Actomyosin | 1 | 2020 | 43 | 0.190 |
Why?
|
User-Computer Interface | 1 | 2021 | 185 | 0.190 |
Why?
|
Laryngeal Neoplasms | 1 | 2020 | 91 | 0.190 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 69 | 0.190 |
Why?
|
Genome, Mitochondrial | 1 | 2019 | 26 | 0.180 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 526 | 0.180 |
Why?
|
Naphthalenes | 1 | 2019 | 45 | 0.180 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2021 | 181 | 0.180 |
Why?
|
Retrospective Studies | 6 | 2023 | 8152 | 0.180 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2019 | 447 | 0.180 |
Why?
|
Treatment Outcome | 7 | 2022 | 7829 | 0.180 |
Why?
|
Mitosis | 2 | 2017 | 149 | 0.180 |
Why?
|
Diagnostic Imaging | 1 | 2023 | 459 | 0.180 |
Why?
|
Cytoskeleton | 1 | 2020 | 186 | 0.180 |
Why?
|
DNA, Mitochondrial | 1 | 2019 | 182 | 0.170 |
Why?
|
Aromatase Inhibitors | 1 | 2018 | 28 | 0.170 |
Why?
|
Quinolines | 1 | 2019 | 94 | 0.170 |
Why?
|
Olfactory Mucosa | 1 | 2018 | 33 | 0.170 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 50 | 0.170 |
Why?
|
Point Mutation | 1 | 2019 | 246 | 0.170 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 135 | 0.170 |
Why?
|
Cell Adhesion | 2 | 2020 | 416 | 0.170 |
Why?
|
Pyrrolidines | 1 | 2018 | 55 | 0.170 |
Why?
|
Gene Rearrangement | 1 | 2019 | 169 | 0.170 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2019 | 102 | 0.170 |
Why?
|
Indoles | 1 | 2020 | 316 | 0.170 |
Why?
|
Lymphocyte Activation | 1 | 2021 | 721 | 0.160 |
Why?
|
Students, Medical | 1 | 2023 | 383 | 0.160 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2018 | 128 | 0.160 |
Why?
|
Prospective Studies | 3 | 2023 | 4091 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 645 | 0.160 |
Why?
|
Computational Biology | 1 | 2021 | 527 | 0.160 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 375 | 0.160 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2019 | 153 | 0.160 |
Why?
|
Capecitabine | 1 | 2017 | 87 | 0.150 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2016 | 14 | 0.150 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 459 | 0.150 |
Why?
|
Logistic Models | 1 | 2020 | 1168 | 0.150 |
Why?
|
Lymph Nodes | 1 | 2020 | 534 | 0.150 |
Why?
|
Lymphocytes | 1 | 2018 | 458 | 0.150 |
Why?
|
Gossypol | 1 | 2016 | 6 | 0.150 |
Why?
|
Signal Transduction | 6 | 2021 | 3198 | 0.150 |
Why?
|
Receptors, Estrogen | 2 | 2016 | 378 | 0.150 |
Why?
|
Trans-Activators | 1 | 2019 | 428 | 0.150 |
Why?
|
Protein Interaction Maps | 1 | 2016 | 48 | 0.150 |
Why?
|
Time Factors | 4 | 2020 | 5179 | 0.150 |
Why?
|
Salvage Therapy | 1 | 2017 | 231 | 0.140 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2021 | 658 | 0.140 |
Why?
|
Immunoconjugates | 1 | 2016 | 102 | 0.140 |
Why?
|
Retinal Dehydrogenase | 1 | 2015 | 6 | 0.140 |
Why?
|
Disease Models, Animal | 5 | 2021 | 2208 | 0.140 |
Why?
|
Taxoids | 1 | 2016 | 129 | 0.140 |
Why?
|
Hyaluronan Receptors | 1 | 2015 | 35 | 0.140 |
Why?
|
Biostatistics | 1 | 2015 | 20 | 0.140 |
Why?
|
Cell Separation | 1 | 2016 | 195 | 0.140 |
Why?
|
Aniline Compounds | 1 | 2015 | 49 | 0.140 |
Why?
|
Risk Factors | 3 | 2021 | 5312 | 0.130 |
Why?
|
Cell Division | 1 | 2016 | 696 | 0.130 |
Why?
|
Statistics as Topic | 1 | 2015 | 234 | 0.130 |
Why?
|
Chemoradiotherapy | 3 | 2022 | 304 | 0.130 |
Why?
|
United States | 3 | 2022 | 6473 | 0.130 |
Why?
|
Isoenzymes | 1 | 2015 | 270 | 0.130 |
Why?
|
Microbiota | 1 | 2020 | 367 | 0.130 |
Why?
|
Crohn Disease | 1 | 2021 | 714 | 0.130 |
Why?
|
Brain Neoplasms | 1 | 2020 | 755 | 0.130 |
Why?
|
Colitis, Ulcerative | 1 | 2021 | 694 | 0.120 |
Why?
|
Tumor Cells, Cultured | 1 | 2016 | 1041 | 0.120 |
Why?
|
Drug Synergism | 3 | 2020 | 302 | 0.120 |
Why?
|
Risk Assessment | 1 | 2021 | 2230 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 424 | 0.120 |
Why?
|
Neoplasm Transplantation | 3 | 2020 | 393 | 0.120 |
Why?
|
Sulfonamides | 1 | 2015 | 296 | 0.120 |
Why?
|
Adult | 10 | 2022 | 25260 | 0.110 |
Why?
|
Disease-Free Survival | 3 | 2022 | 1204 | 0.110 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2011 | 16 | 0.100 |
Why?
|
Mice, Nude | 3 | 2020 | 787 | 0.100 |
Why?
|
Carboplatin | 2 | 2022 | 287 | 0.100 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2011 | 126 | 0.100 |
Why?
|
Apoptosis | 4 | 2018 | 1669 | 0.090 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 53 | 0.090 |
Why?
|
Methylmercury Compounds | 1 | 2009 | 3 | 0.090 |
Why?
|
Milk, Human | 1 | 2009 | 43 | 0.090 |
Why?
|
Hair | 1 | 2009 | 56 | 0.090 |
Why?
|
Lymphatic Metastasis | 2 | 2021 | 480 | 0.090 |
Why?
|
Intelligence | 1 | 2009 | 71 | 0.090 |
Why?
|
Pyrimidines | 1 | 2011 | 368 | 0.080 |
Why?
|
Phenotype | 3 | 2021 | 2346 | 0.080 |
Why?
|
Aged, 80 and over | 4 | 2019 | 6456 | 0.080 |
Why?
|
Models, Theoretical | 2 | 2022 | 475 | 0.080 |
Why?
|
Biomarkers | 2 | 2023 | 1668 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 917 | 0.070 |
Why?
|
Cytokines | 2 | 2021 | 759 | 0.070 |
Why?
|
Endothelial Cells | 2 | 2020 | 410 | 0.070 |
Why?
|
Cell Survival | 2 | 2018 | 967 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 856 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 1955 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 1646 | 0.070 |
Why?
|
Cell Cycle | 2 | 2018 | 502 | 0.070 |
Why?
|
Quality of Life | 2 | 2023 | 1507 | 0.070 |
Why?
|
Reproducibility of Results | 2 | 2021 | 2660 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2017 | 254 | 0.060 |
Why?
|
European Union | 1 | 2023 | 8 | 0.060 |
Why?
|
Pathology, Oral | 1 | 2023 | 5 | 0.060 |
Why?
|
Anthracyclines | 1 | 2022 | 37 | 0.060 |
Why?
|
Adolescent | 3 | 2022 | 8828 | 0.050 |
Why?
|
Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
Tissue Distribution | 1 | 2022 | 288 | 0.050 |
Why?
|
Drug Discovery | 1 | 2023 | 102 | 0.050 |
Why?
|
Interferons | 1 | 2022 | 131 | 0.050 |
Why?
|
Hormones | 1 | 2022 | 140 | 0.050 |
Why?
|
Schools, Medical | 1 | 2023 | 123 | 0.050 |
Why?
|
Albumins | 1 | 2022 | 135 | 0.050 |
Why?
|
Switzerland | 1 | 2021 | 17 | 0.050 |
Why?
|
Republic of Korea | 1 | 2021 | 30 | 0.050 |
Why?
|
Histological Techniques | 1 | 2021 | 35 | 0.050 |
Why?
|
Maximum Tolerated Dose | 1 | 2022 | 271 | 0.050 |
Why?
|
Germany | 1 | 2021 | 72 | 0.050 |
Why?
|
Italy | 1 | 2021 | 104 | 0.050 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 17 | 0.050 |
Why?
|
Models, Animal | 1 | 2022 | 257 | 0.050 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 48 | 0.050 |
Why?
|
T Cell Transcription Factor 1 | 1 | 2021 | 22 | 0.050 |
Why?
|
United Kingdom | 1 | 2021 | 163 | 0.050 |
Why?
|
Japan | 1 | 2021 | 307 | 0.050 |
Why?
|
Shoulder | 1 | 2021 | 39 | 0.050 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 79 | 0.050 |
Why?
|
Induction Chemotherapy | 1 | 2022 | 147 | 0.050 |
Why?
|
Hematoxylin | 1 | 2020 | 6 | 0.050 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2020 | 10 | 0.050 |
Why?
|
TNF Receptor-Associated Factor 3 | 1 | 2020 | 2 | 0.050 |
Why?
|
Fluorouracil | 1 | 2022 | 555 | 0.050 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2020 | 31 | 0.050 |
Why?
|
Patient-Specific Modeling | 1 | 2020 | 19 | 0.050 |
Why?
|
MutL Protein Homolog 1 | 1 | 2020 | 33 | 0.050 |
Why?
|
Mismatch Repair Endonuclease PMS2 | 1 | 2020 | 23 | 0.050 |
Why?
|
MutS Homolog 2 Protein | 1 | 2020 | 30 | 0.050 |
Why?
|
Oncogenic Viruses | 1 | 2020 | 4 | 0.050 |
Why?
|
HCT116 Cells | 1 | 2020 | 149 | 0.050 |
Why?
|
Drug Dosage Calculations | 1 | 2020 | 16 | 0.050 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2020 | 89 | 0.050 |
Why?
|
Neoadjuvant Therapy | 1 | 2022 | 307 | 0.050 |
Why?
|
Environmental Microbiology | 1 | 2020 | 22 | 0.050 |
Why?
|
Whole Genome Sequencing | 1 | 2020 | 74 | 0.050 |
Why?
|
Forkhead Transcription Factors | 1 | 2021 | 164 | 0.050 |
Why?
|
Lymphocyte Depletion | 1 | 2020 | 97 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 18 | 0.050 |
Why?
|
Learning | 1 | 2023 | 270 | 0.050 |
Why?
|
Gastritis | 1 | 2020 | 29 | 0.050 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 543 | 0.050 |
Why?
|
Helicobacter Infections | 1 | 2020 | 34 | 0.050 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 62 | 0.050 |
Why?
|
Circulating Tumor DNA | 1 | 2020 | 36 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2022 | 742 | 0.050 |
Why?
|
Tumor Virus Infections | 1 | 2020 | 81 | 0.050 |
Why?
|
Rad51 Recombinase | 1 | 2020 | 80 | 0.050 |
Why?
|
Benchmarking | 1 | 2020 | 78 | 0.050 |
Why?
|
Gene Amplification | 1 | 2019 | 131 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2020 | 147 | 0.040 |
Why?
|
Survivors | 1 | 2021 | 221 | 0.040 |
Why?
|
Endothelin A Receptor Antagonists | 1 | 2018 | 11 | 0.040 |
Why?
|
Symbiosis | 1 | 2020 | 116 | 0.040 |
Why?
|
Central Nervous System | 1 | 2020 | 151 | 0.040 |
Why?
|
Salivary Glands | 1 | 2018 | 19 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2020 | 190 | 0.040 |
Why?
|
Probiotics | 1 | 2020 | 81 | 0.040 |
Why?
|
Primary Cell Culture | 1 | 2018 | 72 | 0.040 |
Why?
|
Young Adult | 2 | 2022 | 5861 | 0.040 |
Why?
|
Radiation, Ionizing | 1 | 2019 | 120 | 0.040 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2018 | 67 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2019 | 97 | 0.040 |
Why?
|
Genetic Association Studies | 1 | 2020 | 290 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2019 | 348 | 0.040 |
Why?
|
Nasal Cavity | 1 | 2018 | 91 | 0.040 |
Why?
|
Databases, Genetic | 1 | 2019 | 259 | 0.040 |
Why?
|
Carcinogenesis | 1 | 2020 | 190 | 0.040 |
Why?
|
Cadherins | 1 | 2018 | 150 | 0.040 |
Why?
|
ROC Curve | 1 | 2020 | 746 | 0.040 |
Why?
|
Estrogens | 1 | 2018 | 196 | 0.040 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 227 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2020 | 1041 | 0.040 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 19 | 0.040 |
Why?
|
Actins | 1 | 2020 | 441 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 266 | 0.040 |
Why?
|
ErbB Receptors | 1 | 2020 | 481 | 0.040 |
Why?
|
Administration, Oral | 1 | 2018 | 684 | 0.040 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2016 | 9 | 0.040 |
Why?
|
Patient Safety | 1 | 2019 | 213 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2021 | 1519 | 0.040 |
Why?
|
Pandemics | 1 | 2023 | 704 | 0.040 |
Why?
|
Cell Self Renewal | 1 | 2016 | 18 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 1161 | 0.040 |
Why?
|
Antigens, CD | 1 | 2018 | 457 | 0.040 |
Why?
|
Breast | 1 | 2018 | 286 | 0.040 |
Why?
|
Cell Movement | 1 | 2020 | 749 | 0.040 |
Why?
|
Lung | 1 | 2023 | 1135 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 2017 | 108 | 0.040 |
Why?
|
Spiro Compounds | 1 | 2016 | 25 | 0.040 |
Why?
|
Tissue Array Analysis | 1 | 2016 | 124 | 0.040 |
Why?
|
Molecular Imaging | 1 | 2017 | 64 | 0.040 |
Why?
|
Survival Analysis | 1 | 2020 | 1535 | 0.040 |
Why?
|
Benzodiazepines | 1 | 2016 | 64 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 539 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2021 | 1787 | 0.040 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 114 | 0.040 |
Why?
|
Databases, Factual | 1 | 2020 | 792 | 0.040 |
Why?
|
Calcium-Binding Proteins | 1 | 2016 | 114 | 0.040 |
Why?
|
Bacteria | 1 | 2020 | 436 | 0.040 |
Why?
|
G1 Phase | 1 | 2016 | 63 | 0.040 |
Why?
|
CD24 Antigen | 1 | 2015 | 5 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2016 | 162 | 0.040 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 236 | 0.040 |
Why?
|
Heterografts | 1 | 2016 | 99 | 0.040 |
Why?
|
Single-Cell Analysis | 1 | 2017 | 126 | 0.030 |
Why?
|
Neprilysin | 1 | 2015 | 42 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 1547 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2022 | 1181 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2021 | 1756 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2021 | 2788 | 0.030 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 398 | 0.030 |
Why?
|
Pyrroles | 1 | 2016 | 183 | 0.030 |
Why?
|
Microcirculation | 1 | 2015 | 103 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2015 | 74 | 0.030 |
Why?
|
Caspase 3 | 1 | 2015 | 159 | 0.030 |
Why?
|
Binding Sites | 1 | 2018 | 1083 | 0.030 |
Why?
|
Random Allocation | 1 | 2015 | 332 | 0.030 |
Why?
|
Decision Making | 1 | 2020 | 632 | 0.030 |
Why?
|
Protein Binding | 1 | 2018 | 1439 | 0.030 |
Why?
|
Publishing | 1 | 2015 | 88 | 0.030 |
Why?
|
DNA Damage | 1 | 2016 | 361 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2018 | 1747 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2021 | 3050 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 420 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 1202 | 0.030 |
Why?
|
Gastrointestinal Microbiome | 1 | 2020 | 437 | 0.030 |
Why?
|
Child | 2 | 2019 | 6763 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2015 | 673 | 0.030 |
Why?
|
Periodicals as Topic | 1 | 2015 | 167 | 0.030 |
Why?
|
Internet | 1 | 2015 | 309 | 0.030 |
Why?
|
Computer Simulation | 1 | 2018 | 1064 | 0.030 |
Why?
|
Survival Rate | 1 | 2017 | 1852 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 425 | 0.030 |
Why?
|
Pilot Projects | 1 | 2015 | 821 | 0.030 |
Why?
|
Incidence | 1 | 2017 | 1559 | 0.030 |
Why?
|
Phosphorylation | 1 | 2015 | 1094 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2018 | 1416 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 1593 | 0.030 |
Why?
|
Neoplasms, Basal Cell | 1 | 2011 | 9 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 1366 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 2249 | 0.020 |
Why?
|
RNA Interference | 1 | 2011 | 363 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 313 | 0.020 |
Why?
|
Seychelles | 1 | 2009 | 2 | 0.020 |
Why?
|
Mercury | 1 | 2009 | 8 | 0.020 |
Why?
|
Seafood | 1 | 2009 | 10 | 0.020 |
Why?
|
Maternal Exposure | 1 | 2009 | 56 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 1685 | 0.020 |
Why?
|
Internship and Residency | 1 | 2015 | 985 | 0.020 |
Why?
|
Aging | 1 | 2009 | 672 | 0.020 |
Why?
|
Infant | 1 | 2009 | 3000 | 0.010 |
Why?
|
Child, Preschool | 1 | 2009 | 3577 | 0.010 |
Why?
|
Brain | 1 | 2009 | 2161 | 0.010 |
Why?
|